据报道,生物制药公司Galapagos(GLPG)盘前股价暴跌7.09%,引起了市场的广泛关注。公司最新公布的财报显示,其2024财年每股收益较上一年大幅下滑近三分之二,仅为1.12欧元。此前2023财年的第四季度营收和每股收益也较去年同期出现较大幅度回落。
分析人士指出,Galapagos连续两年的业绩下滑可能令投资者对公司未来的增长前景缺乏信心,从而引发抛售股票的行为。公司能否扭转收入和盈利的颓势将是重中之重。
不过,公司最新季报显示营收和每股收益仍超出分析师预期,部分分析师认为这一因素或将对股价构成一定支撑。投资者需要密切关注Galapagos的后续发展,并做好应对风险的准备。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.